|Bid||0.0000 x 1100|
|Ask||0.0000 x 1800|
|Day's Range||1.6500 - 1.8600|
|52 Week Range||0.8500 - 3.5400|
|Beta (5Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020 - Nov 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.31|
New York, New York--(Newsfile Corp. - September 21, 2020) - Soligenix's (NASDAQ: SNGX) RiVax® program is in focus after a failed attempt to send ricin-laced letters to the White House last week raised fresh concerns about the deadly toxin. Those letters, including others addressed to Texas law enforcement agencies, were intercepted before delivery on Thursday. That news helped focus attention toward Soligenix's RiVax® program, which is considered the leading ricin-poisoning vaccine program in the ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and Marburg viruses) and their thermostabilization. The article, authored by collaborators at the University of Colorado, University of Hawaiʻi at Mānoa (UHM) and Soligenix, is titled, "Preservation of Quaternary Structure in Thermostable, Lyophilized Filovirus Glycoprotein Vaccines: A Search for Stability-Indicating Assays" and has been accepted for publication in the Journal of Pharmaceutical Sciences. A copy of manuscript has been made available here.
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Update on COVID-19 Vaccine Candidate CiVax™ On September 10, 2020, Soligenix, Inc. (NASDAQ:SNGX) held a webinar to provide an update on the COVID-19 vaccine landscape and the company’s COVID-19 vaccine candidate CiVax™. According to the World Health Organization ( WHO ), as of Sep. 9, 2020 there are currently 35